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ABSTRACT 
The development and evaluation of a controlled-release (CR) pharmaceutical solid dosage form 
comprising xanthan gum (XG), low molecular weight chitosan (LCS) and metoprolol succinate 
(MS) is reported. The research is, partly, based upon the utilization of computational tools; in 
this case molecular dynamics simulations (MDs) and response surface method (RSM), in order 
to underpin the design/prediction and to minimize the experimental work required to achieve 
the desired pharmaceutical outcomes. The capability of the system to control the release of MS 
was studied as a function of LCS (% w/w) and total polymer (LCS and XG) to drug ratio (P:D) 
at different tablet tensile strengths. MDs trajectories, obtained by using different ratios of 
XG:LCS as well as XG and high molecular weight CS (HCS), showed that the driving force 
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for the interaction between XG and LCS is electrostatic in nature, the most favourable complex 
is formed when LCS is used at 15 % (w/w) and, importantly, that the interaction between XG 
and LCS is more favourable than that between XG and HCS. RSM outputs revealed that the 
release of the drug from the LCS/XG matrix is highly dependent on both the % LCS and the 
P:D ratio and that the required CR effect can be achieved when using weight fractions of LCS 
≤ 20% and P:D ratios ≥ 2.6:1. Results obtained from in-vitro drug release and swelling studies 
on the prepared tablets showed that using LCS at the weight fractions suggested by MDs and 
RSM data plays a major role in overcoming the high sensitivity of the controlled drug release 
effect of XG on ionic strength and pH changes of the dissolution media. In addition, it was 
found that polymer relaxation is the major contributor to the release of MS from LCS-XG 
tablets. Using Raman spectroscopy, MS was shown to be localized more in the core of the 
tablets at the initial stages of dissolution due to film formation between LCS and XG on the 
tablet surface which prevents excess water penetration into the matrix. In the later stages of the 
dissolution process, the film starts to dissolve/erode allowing full tablet hydration and a 
uniform drug distribution in the swollen tablet.  
Keywords: Low molecular weight chitosan, xanthan gum, molecular dynamics simulations, 
response surface method, controlled-release polymeric matrices, pharmaceutical formulation, 
tablet swelling, Raman mapping, metoprolol succinate. 
Introduction 
Oral controlled release (CR) drug delivery systems are generally manufactured by utilizing 
special devices and complex techniques.1 The most commonly used CR systems are osmotic 
pump systems, coating techniques, and reservoir devices.2,3 The high cost of the equipment 
used, in addition to the complexity of the methods employed, present a tangible problem for 
continuous, large-scale manufacturing of CR systems. Arguably, monolithic systems (where 
the drug is dissolved/dispersed in a polymeric matrix) constitute a more convenient alternative 
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compared to relatively complicated CR device preparation methods.4 They offer the advantage 
of utilizing conventional dosage form manufacturing processes using equipment commonly 
available in any pharmaceutical manufacturing facility.5 Synthetic and natural polymers are 
often used for the preparation of such dosage forms. Natural polymers are preferred since they 
are abundant, biocompatible, biodegradable and cost-effective.6 Commonly used natural 
polymers in CR systems include derivatives or salts of cellulose, chitosan, alginate, xanthan 
gum (XG) and galactomannan.7–9 
XG is recognized as one of the most efficient natural occurring polymers for use in retarding 
the release of active pharmaceutical ingredients (APIs) owing to its high water uptake ability 
and stability against enzymatic degradation in the gastrointestinal tract.10,11 In addition, XG is 
biocompatible and is fully degraded by the bacteria of the colon.12 It has been employed to 
control the release of various APIs.13–15 XG is a branched hetero-polysaccharide which is 
produced by the microorganism species Xanthomonas.5 It is composed of a cellulosic backbone 
and side-chains consisting of two D-mannose and D-glucuronic acid moieties, in addition to a 
pyruvic acid group on about half of the terminal D-mannose monomers.16 Native XG displays 
an ordered single or double helical conformation which is stabilized by intramolecular 
hydrogen bonds.17 In solution, repulsion occurs between XG chains due to the ionization of 
acidic glucuronic and pyruvate functional groups; thus, XG adopts a flexible coil 
conformation.18 Increasing the concentration of ionic species in solutions of XG causes the 
renaturation of XG to a rigid double-stranded helix conformation.19 As a result, the water 
uptake ability of XG is reduced and a greater fraction of the incorporated API is released from 
the matrix.20 The high dependence of XG gelling and release behavior on ionic strength 
hampers its widespread utilization in drug delivery.18 Attempts to overcome this drawback 
were the impetus for combining XG with a second polymer i.e., to minimize the effect of the 
surrounding environment and enhance the drug retardation properties of XG. A wide variety 
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of polymers have been investigated for such purposes e.g., galactomannan, guar gum, HPMC, 
starch, PVA, carrageenan, Carbopol and gellan.11,21–23 Such polymers are either anionic or non-
ionic and interact with XG via weak van der Waals intermolecular forces attaining a synergetic 
CR effect with XG;24 hence, enhancing the overall retardation of APIs. Therefore, the 
drawbacks found in the use of each individual polymer are less pronounced, but not eliminated.  
Owing to the anionic nature of XG, the combination of chitosan (CS) and XG has been widely 
investigated to control the release of APIs and biomolecules. The unique positive net charge of 
CS in addition to its other favourable properties, such as biocompatibility and                           
muco-adhesivity, makes it one of the most investigated co-polymers with XG.25 XG-CS binary 
mixtures form an insoluble gel layer when exposed to aqueous media.26 This is due to 
polyelectrolyte complexation between oppositely charged functional groups of CS and XG.27 
The aforementioned combination has been found to provide a CR effect with a wide range of 
drugs.28–31 In the literature, the focus of the majority of the research conducted has been on CR 
drug delivery utilizing high molecular weight chitosan (HCS) with XG. Most of the results 
reported demonstrate that in order to exert the highest drug retardation effect, CS is best used 
with XG at a weight fraction of 50%.9,20,32 Although the forgoing matrix was capable of 
hindering the release of incorporated drugs, the drug release displayed a pH-dependency 
behaviour and was affected by the ionic strength of the dissolution media. Few reports in the 
literature have considered the pH dependency of CS matrices as an advatange to develop 
targeted drug delivery systems.33,34 Others have attempted to overcome this shortcoming by 
altering the chemical structure of CS. Chemical modification of CS has been used to enhance 
a specific physicochemical property such as solubility, stability or biological effects e.g., 
mucoadhesion, cell penetration and antimicrobial effects.35–37 Since the molecular weight 
(MW) of CS is the major contributor toward its solubility and interaction with other molecules, 
low molecular weight chitosan (LCS) has been prepared and studied in the literature in order 
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to address the effect of MW on the drug release behaviour from CS-XG matrices. The MW of 
CS has a profound effect on the water uptake capacity of CS-XG matrices.38 HCS exhibits low 
water absorption capacity from the dissolution media when compared to LCS. The increase in 
water absorption causes the formation of more polyelectrolyte complex (PEC) layers which 
results in potentially more drug retardation. In addition, lower release rates of diclofenac 
sodium were obtained when incorporated in XG tablets comprising LCS (13 and 30 kDa).39 
Another study confirms the previous finding whereby terbutaline sulfate showed slower release 
from XG-LCS compared to XG-HCS.30 Although LCS in the aforementioned studies showed 
a better CR effect than HCS when combined with XG, a full optimisation of the formulation 
and a detailed study of its effect on XG sensitivity to pH and ionic strength were not addressed.  
Metoprolol succinate (MS) was selected as the model drug in this study due to its high aqueous 
solubility and short biological half-life. MS is a cardio-selective -blocker used to manage 
angina, acute myocardial infarction, hypertension and to prevent heart attacks.40 It is a class I 
drug, according to the Biopharmaceutics Classification System (BCS), that shows rapid 
absorption from the GIT following oral administration.41 Due to its quite short biological      
half-life (3-7 h) and rapid absorption, metoprolol serves as an ideal candidate for oral CR 
delivery. Since metoprolol free base is considerably unstable, metoprolol tartrate and succinate 
are the most common salts used for tablet preparations. MS (Figure 1) is available as a CR 
product marketed by AstraZeneca (Betaloc® ZOK). Therefore, it was considered as the 
reference formulation to test the suitability of the drug release matrix.  
 
Figure 1 Schematic of the chemical structure of MS. 
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The objective of the current work was to use scientific evidence to design, formulate and 
optimize a CR solid matrix system based on polymers, LCS and XG, from biological sources. 
The foregoing was achieved by: (i) utilizing computational tools/molecular dynamics (MDs) 
simulations to achieve a broad understanding of the molecular interaction(s) between the 
studied biopolymers in a way that helps to predict and design the experiments, (ii) evaluate the 
factors involved in the CR performance of the prepared matrices, and predict the set of 
parameters that will result in the optimum CR effect using response surface method (RSM), 
(iii) address the superiority of LCS over HCS in controlling the release of APIs from XG-CS 
based matrices and in overcoming the limitations of XG as a CR agent, and (iv) employing 
Raman mapping to evaluate the performance of the prepared matrix and obtain an explanation 
of the tablet swelling process and drug release mechanism from the developed delivery system.  
Experimental section 
Materials  
LCS with average molecular weight of 13 KDa having an average particle size of ~100 µm, 
viscosity of 11 mPas (1% w/v in water), and degree of deacetylation > 95 % was purchased 
from G.T.C. Union Group Ltd, China (batch No. GC20140503). HCS with an average 
molecular weight of 150 KDa, average particle size of ~100 µm, viscosity of 150 mPas (1% 
w/v in water), and degree of deacetylation > 90 % was purchased from the same source (batch 
No. GC20140510). XG having a viscosity range of 1400-1600 mPa, (1% w/v in water), and 
average particle size of < 180 µm was purchased from Jungbunzlauer GmbH, Ladenburg, 
Germany (batch No. 2504519). USP grade metoprolol succinate (MS) was obtained from Ipca 
Laboratories Ltd., Mumbai, India (batch No. A0337986). Betaloc® ZOK (AstraZeneca AB, 
Sodertalje, Sweden) was used as a reference product for MS. All other materials and reagents 
used were of analytical grade and accessed from the Jordanian Pharmaceutical Manufacturing 
Co., (JPM), Naor, Jordan. 
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Computational methods (molecular dynamics simulations, MDs) 
AMBER11 software was used to run the MDs by employing the GLYCAM06 force field.42,43 
Initial structures and geometries for XG, LCS and HCS were obtained using the carbohydrate 
builder database tool provided by the official GLYCAM website.44 Four monomers were used 
to build the XG molecule whereas LCS molecules, at different XG: LCS ratios, were built as 
dimers. In the case of HCS, the molecule was built using nine monomers of glucosamine. 
Atomic charges were obtained from the force field and the protonation state of both polymers 
was chosen to mimic the in-vitro release experimental conditions (pH 6.8). Each system was 
then solvated in a TIP3P periodic box water model whereby counter-ions (sodium and chloride) 
were added to preserve the neutrality of the systems investigated. Periodic boundary conditions 
were applied. The non-bonded cut-off was set at 12.0 Å and electrostatic interactions were 
treated using the Particle Mesh Ewald (PME) method.45 Energy minimization was carried out 
for each system, followed by heating to 298 K. A total of 50 ns MD simulations were run using 
the NPT ensemble to a Berendsen thermostat at 298 K and a barostat at 1 atm. 
VMD 1.8.6 software was utilized to visualize the resulting MDs trajectories.46 MDs analysis 
were performed using the PTRAJ module of the AMBER 11 tools MDs package.43 
Calculations of binding free energy (∆G) for each complex were conducted using the molecular 
mechanics/Poisson–Boltzmann surface area (MM-PBSA) method. Equation 1 was used to 
calculate the binding free energy:47 
Equation 1. 
∆G = ∆E + ∆Gsolv - T∆S 
where ∆Gsolv is the free energy of solvation; ∆E is the gas phase interaction energy and is 
computed as per equation 2, and TΔS is the conformational entropy of the system.  
Equation 2. 
∆E = ∆Eelec + ∆EvdW + ∆EINT 
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where ∆Eelec is the electrostatic energy, ∆EvdW is the van der Waals interaction energy and 
∆EINT is the internal energy.  
On the other hand, ∆Gsolv is composed of the sum of polar (∆GPB) and non-polar (∆GNP) 
interactions and is obtained via equation 3. 
Equation 3. 
∆Gsolv = ∆GPB + ∆GNP 
Preparation and characterization of compacts 
MS, XG and LCS powders were, separately, passed through a sieve with a mesh size of 250 
μm and collected on a 90 μm mesh. Raw polymers as well as mixtures of XG and LCS (at LCS 
mass percentages of 15, 25, 35 and 50%) were weighed using an electronic balance. Polymer 
mixtures were used with or without 95 mg of the drug MS. Polymers or polymers with drug 
were physically mixed and then directly compressed using a single punch tablet press 
(Manesty, Merseyside, UK). Samples were filled in a 12-mm circular die with flat-faced 
punches. Compression was carried out at different forces (in the range of 25-45 units as per the 
scale provided by the tablet press) in order to obtain tablets with tensile strengths of 0.7, 2.4 
and 3.7 N/m2 (± 0.1). Tablet thickness for the formulation constituted of 15 % LCS was 
3.7±0.05 mm. The crushing strength of the prepared tablets, which was used for the calculation 
of tensile strength, was measured using a hardness tester (Pharma Test PTF E. Hainburg, 
Germany).  
Response surface method (RSM) 
The simultaneous effect of the percentage of LCS (A) and polymer-to-drug (P: D) ratio (B), as 
well as tensile strength (C) on the efficiency of LCS-XG matrices as CR carriers for MS were 
examined by assigning them as independent variables. While the cumulative drug release from 
tablets at time intervals of 1 (Y1), 4 (Y2), 8 (Y3) and 20 h (Y4) were assigned as the responses 
(dependent variables). For each variable, three levels were used; lower, middle and upper. The 
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effect of independent variables upon the responses was described using different polynomial 
equations for the various measured responses. Design-Expert® software version 10.0.1.0  
(Stat-Ease, Inc., Minneapolis, USA) was employed. A total of 27 runs of in-vitro release trials 
were conducted to collect enough data to build mathematical models and thus generate the 
necessary contour plots. The goodness-of-fit of the suggested models was established using the 
coefficient of determination (R-squared, R2). ANOVA analysis were conducted for the 
suggested models. A model was considered significant when p-values were less than 0.05. 
In-vitro release studies of MS from XG-LCS tablets 
In-vitro release studies were conducted using USP apparatus II (Labindia DS8000, Labindia 
Analytical Instruments Pvt. Ltd., New Delhi, India) in 500 ml phosphate buffer pH 6.8 at 
37±0.5 °C and 50 rpm rotation speed; the foregoing parameters comply with USP32-NF27 
specifications. Samples (10 ml) were withdrawn at time intervals of 1, 2, 4, 6, 8, 12, 16 and    
20 h and replaced with an equivalent volume of the dissolution medium. Sample aliquots were 
passed through 0.7 µm membrane filters and analysed by UV spectrophotometry (LABINDIA 
UV/VIS Spectrophotometer UV 3000+, Maharashtra, India) at 274 nm and 2 nm spectral 
bandwidth. 1 cm quartz cells were used to measure the absorbance of the samples and results 
were recorded using UVWin 5 software. A stock solution of 1 mg/mL of MS was prepared by 
accurately weighing 100 mg MS and dissolving it in 100 mL deionized water. Standard 
solutions were prepared from the stock solution to generate the calibration curve. The UV 
method of analysis of MS was validated in compliance with the International Conference on 
Harmonization (ICH) 2QB guidelines for validation of analytical procedures.48 The linearity 
(R2= 0.9999), linear range (40-200 µg/mL), limit of detection (7.8 µg/mL) and limit of 
quantitation (23.7 µg/mL) for the analysis of the drug were established from the data obtained. 
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Water uptake (swelling) and matrix erosion measurements of tablets 
Tablets were placed in a USP dissolution apparatus II (Labindia DS8000, Labindia Analytical 
Instruments Pvt. Ltd., New Delhi, India) using the same experimental conditions described in 
the in-vitro release section. At pre-determined time intervals tablets were detached, carefully 
blotted on adsorbent tissue to remove excess water and weighed using an electronic balance 
with a resolution of 0.1 mg (AG245, Mettler Toledo, Ohio, United States). The swollen tablets 
were left to dry at ambient temperature for 24 h, incubated in a vacuum oven at 25 °C for 12 h 
before determining the dry weight. Tablets were incubated again in the vacuum oven for an 
extra 12 h in order to ensure that the weight of the dried tablets was consistent. When needed, 
the drying cycles were repeated until a constant weight was achieved. The cumulative 
percentage swelling and remaining mass of the tablets at each time point were determined using 
equations 4 and 5, respectively. 
Equation 4. 
Swelling (%) = (
Xst − X0
X0
) ×  100 
Equation 5. 
Remaining mass (%) = (
Xdt
X0
)  ×  100 
where X0 is the initial weight of the tablet, whilst Xst and Xdt represent the weight of the swollen 
and the dried tablets at time t, respectively. 
Evaluating the drug distribution during dissolution using Raman mapping  
Raman mapping was used to monitor drug distribution between the two regions (dry core and 
hydrated gel layer) of the tablets. Swollen tablets were withdrawn from the dissolution vessels 
at time intervals of 1, 2, 4, 8 and 12 h, carefully blotted on absorbent paper to remove excess 
water and cut in halves. A Horiba LabRam I spectrometer (Horiba Jobin Yvon Ltd., UK) 
equipped with an automated XYZ stage (Märzhäuser) and Olympus BX40 microscope was 
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used in this study. The instrument was calibrated using a silicon band at 520.7 cm-1. Raman 
spectra were acquired by employing a near-IR laser (785 nm) providing an excitation power of 
100 mW, 10× Olympus objective, 1200 lines/mm grating and a Synapse Peltier-cooled CCD 
detector. Raman maps were generated by collecting the spectra for an area of 720 × 720 μm 
from each region of the tablets. The grid spacing between each point was 24 μm for both             
the x-axis and the y-axis, and a total of 900 spectra per map were collected. SWIFT mode was 
utilized to allow rapid mapping and avoid drug migration between the different tablet layers 
during measurements. The acquisition time was set to 0.5 seconds per spectrum and the 
LabSpec 6 (Horiba Jobin Yvon Ltd., UK) software package was used to collect the spectra and 
maps. 
In-vitro evaluation of the effect of pH, ionic strength and the presence of ethanol in 
dissolution media on the rate of drug release and dose dumping 
The impact of ionic strength (µ) on the release rate of MS from the matrix was assessed by 
adding NaCl to phosphate buffer at concentrations of 0.1, 0.2 and 0.4 M. The effect of pH was 
evaluated by testing the release of MS from prepared compacts in three different media            
(pH 1.2, 4.5 and 6.8). In accordance with FDA guidelines,49 dose dumping studies were carried 
out in the presence of ethanol. Dissolution tests were carried out using USP II apparatus at       
37±0.5 °C and 50 rpm rotation speed. Vessels were filled with 500 ml HCl 0.1N containing 
ethanol at concentrations of 5, 20 and 40% (v/v). Samples (10 ml) were collected for 2 h and 
the release of MS from the LCS/XG preparation was compared to the reference product.  
Statistical analysis 
Calculations were carried out using Excel 2016 (Microsoft, USA). Data represents the mean ± 
standard deviation. The 2-D schematic structures of the studied compounds were built using 
ACD/ChemSketch 2017.2.1 (Advanced Chemistry Development, Inc., Toronto, ON, Canada) 
software. Data plots were generated using Excel 2016 software (Microsoft, USA).  
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Results and discussion 
Molecular dynamic simulations (MDs) 
MDs were utilized in this work in order to explain the mechanism of interaction between LCS 
and XG and to find/predict the XG: LCS ratio that would result in the most favourable 
interaction between the two biopolymers. In previous MDs work, we reported that electrostatic 
interactions are responsible for complex formation and stabilization between LCS and XG at a 
single interaction ratio of 1:1.50 In addition, we found that protonation of amine groups in LCS 
is the most important factor affecting the interaction between the two polymers. In the current 
study, we have extended the previous MDs work and investigated the interaction between LCS 
and XG at different ratios and at a fixed protonation state in accordance with the pH of the 
dissolution medium used in the experimental studies. Ratios of LCS/XG were converted from 
(w/w) to molar ratios to mimic experimental conditions.  
Root mean square deviation (RMSD) data indicates how far molecules have migrated from 
their initial structures during the MDs (Figure 2a). It was found that complexes with LCS 
values ≥ 25% exhibited a pronounced deviation from their initial structures with high 
fluctuations, from about 8 to 22 Å, during the MDs. Complexes with lower percentages of LCS, 
15%, displayed lower movement (< 10 Å) with minor fluctuations. The observed deviations, 
which indicate instability of the resultant complexes, was in the order 50 > 35 > 25 > 15% of 
LCS. Importantly, the fluctuation in the mean distances decreased after ~ 10 ns for LCS/XG 
complex constituted of 15% LCS and ~ 30-40 ns for complexes composed of 25-50% of LCS 
indicating that the systems need 30-40 ns to stabilize and equilibrate during the MDs. Thus, 





Figure 2 (a) RMSD values for LCS-XG mixtures; values on the lower right corner represent the % LCS 
(w/w). (b) Calculated average Rg and end-to-end distance values for XG chains during the 50-ns 
simulation of LCS-XG mixtures at different % of LCS. Error bars represent SD values, * denotes 
insignificant differences in the average Rg values of LCS-XG complexes from the average Rg value of 
XG alone (0% LCS, p>0.05), whereas ** denotes a significant difference (p<0.05). 
The average structure of each polymer mixture showed that LCS molecules are embedded 
between the backbone and the peripheral chains of XG (Figure 3). Increasing the number of 
LCS molecules resulted in a less favoured interaction between the two polymers in which less 







Figure 3 Average structures of LCS-XG mixtures obtained using MDs at LCS values of: (a) 15, (b) 25, 
(c) 35, and (d) 50%. XG is represented in line model mode whereas LCS is represented in the VDW 
model mode. Hydrogen atoms were excluded for clarity, oxygen atoms are displayed in red, carbon in 
cyan, and nitrogen in blue.  
Molecular mechanics/Poisson–Boltzmann surface areas (MM-PBSA) was used to compute the 
binding free energies of the studied complexes (Table 1). Results revealed that electrostatic 
forces (polar interactions) between the two polymers are the major contributor towards the 
formation and stability of LCS-XG complexes, which is in accord with our previous work.50 
The existence of oppositely charged groups, NH3
+ in LCS and COO- in XG, in the structure of 
the polymers gives rise to the electrostatic forces. Increasing the content of LCS resulted in a 
higher positive charge density within the mixture, owing to the cationic amine groups. As a 
result, repulsion between LCS molecules occurs causing a substantial increase in the movement 
and fluctuation of atoms when the LCS content is > 25%, as was addressed by RMSD results. 
Hence, the contact and interaction of LCS molecules with XG decrease and less stable 
complexes are formed. To a much lower extent, Van der Waals forces (∆EvdW) also play a role 













positive values of the solvation free energy (∆Gsolv) demonstrate the formation of insoluble 
complexes between LCS and XG at all ratios. The total free energy of binding (∆G) was 
computed for the studied complexes. ∆G values are negative for all complexes indicating 
favourable interactions between LCS and XG at all mixing ratios. However, it is noticeable 
that increasing the fraction of LCS results in less favourable interactions, which correlates well 
with both the RMSD results and the average structure snapshots. The most stable complex 
between LCS and XG is formed at LCS contents of 15%. It is noticeable that the total 
interaction energy (∆E) between XG and LCS increases with the % LCS, indicating more 
deviation of the molecules from their initial structures. However, ∆E values are compensated 
by the high negative entropy (T∆S) values which suggests a reduced conformational flexibility 
of the molecules upon complexation. Thus, XG and 15% LCS formed the most favourable 
complex. Increasing LCS content to 25% resulted in ~ 8 kcal/mol decrease in ∆G. No 
significant decrease in ∆G values were found in LCS-XG mixtures containing > 25% LCS 
comparing to 25% LCS. 
Table 1 MM-PBSA results for the LCS-XG mixtures at different % (w/w) of LCS.  
LCS (% w/w)  ∆Eeleca   ∆EvdWa       ∆Gsolva   ∆Ea T∆Sa ∆Ga 
15% -256.41 ± 45.8 -18.11 ± 05.5 249.49 ± 36.6 -25.04 ± 11.8   3.35c -28.39 
25% -484.72 ± 75.9 -43.70 ± 10.8 484.68 ± 70.9 -43.76 ± 0.13 -23.09 -20.65 
35% -620.20 ± 46.5 -47.14 ± 06.9 616.41 ± 43.9 -50.63 ± 0.14 -30.98 -19.65 
50% -1747.9 ± 63.6 -90.02 ± 09.1 1720.1 ± 59.2 -117.8 ± 16.6 -97.45 -20.35 
HCSb -604.56 ± 57.9 -55.63 ± 08.8 655.33 ± 62.4 -04.99 ± 04.7 -31.50  26.61c 
a Values shown are in kcal/mol. b Energy values represent the MMPBSA results for a single chain HCS molecule 
with XG. c Note that these values are positive. 
In order to elucidate the conformational flexibility of XG during MDs, the radius of gyration 
(Rg) and end-to-end distances of XG chain were calculated for all complexes (Figure 2b). Rg 
is a property that describes the conformational flexibility of polymers; it gives an indication of 
whether the polymer chains are extended or folded. Average values of Rg and end-to-end 
distance for XG exhibited a decrease in both 15 and 25% LCS complexes compared to the 
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values obtained from XG alone (0% LCS), being more pronounced in XG-LCS 15%. This 
suggests a flexible conformation of XG whereby the chains are folding to interact with LCS. 
This is in accord with results obtained from the average structure, indicates that the system is 
reaching equilibrium51 and that the interaction between XG and LCS is favoured, as shown by 
the free energy values. A restriction in the flexibility of XG can be noticed when increasing the 
ratio of LCS to 35% with the backbone being more extended causing a reduction in the contact 
with LCS which is obvious from both the average structure and MMPBSA results. When the 
LCS ratio reached 50%, a slight reduction in the Rg and end-to-end distance values of XG was 
noted compared to the 35% LCS complex suggesting either no change in the conformation of 
XG when LCS is incorporated at percentages ≥ 35%, or that the maximum extended structure 
of XG was obtained when combining it with LCS at 35%. This is in accord with the MMPBSA 
results which suggest that the least favourable complex is formed when the LCS ratio is 35%. 
To justify the chosen molecular weight of CS and assess the benefit of using LCS compared to 
HCS, an MD simulation was carried out between XG and HCS using a single long-chained CS 
molecule (9 monomers).  The average structure, Figure 4a, exhibited good contact between the 
HCS and XG molecules. However, RMSD calculations (Figure 4b) showed a higher deviation 
from the starting structure compared to the MD simulation data for XG with a single LCS 
molecule (dimer). In addition, a high fluctuation can be noticed for the first 30 ns of the HCS 
trajectory whereas the LCS took around 10 ns to reach equilibrium and the most favourable 
conformation. End-to-end distance of the XG backbone was measured from both LCS and HCS 
trajectories to address the effect of CS molecular weight on the flexibility of XG during MDs. 
It can be noticed from the data presented in Figure 4c that the XG chain is more flexible and 
favours a more folded structure when allowed to interact with LCS, reaching distances as low 
as 25 Å, whereas when it was interacted with HCS a more rigid and expanded structure was 




Figure 4 (a) Average structures of HCS-XG obtained from 50 ns MDs. The XG molecule is presented 
in line model mode, whereas HCS is in the VDW model mode; (b) RMSD values obtained during the 
simulation time for complexes comprising XG with a single LCS dimer and HCS molecules; (c) end-






A plausible explanation for the results obtained is that LCS retains the backbone structure of 
HCS but displays a less crystalline structure.52 In addition, intra-molecular hydrogen bonds and 
Van der Waals forces are reduced as a result of decreasing chain length.53 Consequently, the 
free mobility of LCS molecules is increased, they become soluble in water/neutral solutions, 
and interact more readily with other molecules.5 Therefore, LCS was used with XG to optimize 
and evaluate a hydrophilic solid matrix to control the release of the model drug MS. 
Response surface method (RSM) 
Response surface method (RSM) is a design of experiment tool that is used to gauge the 
significance of each selected factor on the responses and to predict the correlation and 
interaction between experimental variables so that the response can be optimized accordingly.54 
In addition, it offers the advantage of weighing the effect of several variables on more than one 
response at the same time. RSM was utilized to test our MDs findings of the optimum mass 
fraction of LCS and to optimize the final formulation depending on the effect of the P:D ratio 
and LCS% at different tensile strength values on the retardation efficiency of the formed 
compacts. All input variables were subjected to multiple model fitting and linear regression 
followed by ANOVA to find the model that shows the best correlation between predicted and 
actual values. Probability p-values < 0.05 indicate the significance of the model whereas              
the f-value relates the outcomes to the noise in which values > 3.5 imply an adequate 
significance of the model over the noise (as specified by Design Expert®). Adequate precision 
(Adeq pre) measures the signal to noise ratio; a value greater than 4 is desirable. In general, the 
higher the R-squared (R2) value the better the model fits the data. A difference between 
predicted R-squared (Pred R2) and adjusted R-squared (Adj R2) of less than 0.2 indicates the 
validity of the selected model. Generated polynomial models and equations imply the high 
dependence of drug release from the matrix on both the percentage of LCS (A) and the P:D (B) 
values. The analysis showed that the best goodness-of-fit result was obtained for the quadratic 
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polynomial model. The summary model data for each response is presented in Table 2. 
Calculated p, f and adequate precision values denote the significance and the validity of the 
quadratic polynomial model in describing the correlation between independent variables and 
responses. Generated equations can predict from 91% (Y4) up to 99.5 % (Y1 and Y2) of drug 
release data points as implied by R2 values.   
Table 2 Summary data for each model and ANOVA results of studied variables and responses. 
Response p-value f-value R2 Pred R2 Adj R2 Adeq pre Equation*  
Y1 (1 h) 0.0001 367.67 0.9949 0.9876 0.9922 45.61 Y1= 18.21+40.14A-4.71B-1.8C-8.036×10-3 AB 
+0.34AC-0.45BC+36.51A2+2.48B2+1.17C2 
Y2 (4 h) 0.0001 353.04 0.9947 0.9854 0.9919 52.69 Y2= 55.43+30.19A-4.22B-2.89C+2.55AB+ 
2.34AC-0.37BC+11.59A2+1.46B2+1.90C2 
Y3 (8 h) 0.0482 107.71 0.9828 0.9560 0.9736 31.71 Y3= 75.64+19.77A-5.14B-1.85C+3.76AB+ 
1.07AC-0.028BC+3.36A2+0.048B2+1.31C2 
Y4 (20 h) 0.0009 19.250 0.9107 0.7682 0.8634 16.90 Y4= 98.89+4.34A-1.04B-2.05C+1.49AB+ 
2.92AC-0.16BC-3.80A2+0.24B2+0.79C2 
* Dependent variables are: (A) LCS%, (B) P:D, and (C) tensile strength 
Contour plots illustrating the design space (blue area) and showing the effect of LCS% (A) and 
polymer to drug P:D ratio (B) on the release of the drug from XG-LCS tablets at different 
tensile strengths (C) are presented in Figure 5. Acceptance criteria data for the release of MS 
from controlled-release tablets, as specified by USP32-NF27, are presented in Table 3. The 
initial release of MS after 1 h shows that tablets containing up to 50% LCS at any P:D ratio 
meet the USP criteria. With the lapse of time, in relation to responses (Y2 and Y3) which 
represent time intervals (4 and 8 h, respectively), the design space that fulfils USP requirements 
was narrowed (blue area). At low tensile strength (0.7 N/m2), the design space was limited to 
the use of no more than 15% LCS at a P:D ratio of 4:1 after 8 h, whereas if a P:D ratio of 3:1 
was adopted, pure XG should be used to control the release of MS. Increasing the tensile 
strength to 3.7 N/m2 resulted in more flexibility in design space allowing the incorporation of 
around 25% LCS and a total P:D ratio of 2.2:1. Tablets at all P:D ratios and % LCS showed 




Figure 5 Contour plots of drug release from LCS-XG based tablets as a function of (A) % LCS, (B) 
P:D ratio and (C) tensile strength of prepared tablets at: (Y1) 1 h, (Y2) 4 h, (Y3) 8 h, and (Y4) 20 h.  































Table 3 USP acceptance criteria for MS controlled release tablets. 
Time (h) Amount dissolved 
1 NMT* 25% 
4 20% - 40% 
8 40% - 60% 
20 NLT** 80% 
* NMT: not more than, and ** NLT: not less than 
The results obtained from RSM are in accordance with the results of Mundada et al. who found 
that the P:D play a major role in controlling the release of MS using various cellulosic and 
acrylic polymers derivatives.55 In addition, Gohel et al. reported a high dependency of MS 
release rate from wet granulated tablets on the ratio of XG and HPMC in the tablet.56 This can 
be explained by the longer path MS needs to travel when the ratio of the polymer(s), XG and 
LCS in our case, is increased in the tablet.57 
The overall design space (yellow area, Figure 6) for the optimum release of MS from XG-LCS 
based tablets at a tensile strength of 2.4 N/m2 (which was adopted in this study) suggests that 
at a P:D ratio of 4:1 the ability to control the release of MS can be exerted using LCS at 
percentages up to around 20%. When using the lowest possible P:D ratio in the design space   
(~ 2.6:1), the model output endorses the use of XG alone to maintain the retardation efficiency 
of the matrix. Hence, in order to examine the advantage of incorporating LCS in the 
preparation, further in-vitro evaluation (swelling and dissolution studies) were carried out.  
 
Figure 6 Design space (yellow area) representing the optimum combination of variables for the CR 
delivery of MS from LCS-XG tablets. (A) LCS (%) and (B) P:D ratio. (C= 2.4 N/m2). 
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In-vitro release dissolution and tablets swelling studies 
The in-vitro release profiles for MS from LCS-XG tablets at different mass fractions of LCS 
are presented in Figure 7a. A P:D ratio of 4:1 was adopted from the design space obtained using 
RSM (Figure 6). MS showed an immediate release pattern when incorporated with LCS as the 
sole polymer. This behavior was expected since the retardation ability of hydrophilic polymers 
is directly proportional to their viscosity (molecular weight).58 Therefore, LCS alone is not 
suitable for drug retardation and the maximum used weight percentage was limited to 50%. On 
the other hand, XG was able to retard the release of MS. Tablets prepared from the binary 
biopolymers mixture were capable of sustaining the release of MS at all incorporated LCS mass 
ratios. The pattern of drug release was inversely proportional to the % LCS. Almost half of the 
incorporated drug dose was preserved in tablets containing 15% LCS after 8 h, whereas ~85% 
of the dose was released after 8 h from tablets constituted of 50% LCS. This is in agreement 
with the findings of Varshosaz et al who examined the release of MS from tablets comprising 
XG with guar gum.59 They found that tablets containing higher ratios of XG displayed higher 
drug retardation ability.  
The drug retardation capability of LCS/XG mixtures can be explained by polyelectrolyte 
complexation. Once tablets are in contact with the dissolution medium, PECs start to form 
between XG and LCS on the surface of the tablets. This is due to ionic interactions between 
the oppositely charged polymers.26 This was confirmed by the outcomes of MDs which showed 
that the main contributor for the interaction between XG and LCS is electrostatic forces. 
Although the formed PECs are physically cross-linked, they were able to render the release of 
MS from the LCS-XG matrices. Thus, PECs can serve as alternatives to chemically cross-
linked hydrogels (using e.g., chemical cross-linkers such as glutaraldehyde) offering the 





Figure 7 (a) In-vitro release profiles of MS from prepared compacts and the reference product, Betaloc® 
ZOK in phosphate buffer pH 6.8. Values represent mean ± SD (n=12); (b) Degree of swelling of the 
XG and LCS/XG matrix tablets in phosphate buffer, pH 6.8. Values represent mean ± SD (n=6). 
The percentage weight gain (swelling) of the hydrated XG-LCS matrices was measured for     
20 h (Figure 7b). Pure XG showed rapid and high levels of hydration where the tablet weight 





predicted considering the high-water uptake capacity and rapid weight gain of tablets 
comprising XG.56 In contrast, LCS based tablets fully disintegrated within the first hour of the 
experiments showing no hydration capability. Thus, measurements for the degree of swelling 
were not obtainable for LCS. This is in accord with the immediate release behavior of LCS 
formulations in dissolution studies and with the results of Ritthidej et al., who investigated the 
capability of using CS as a disintegrant in tablets and found that CS can be used as an effective 
disintegrant in tablet formulations.60 In the case of LCS/XG matrices, it is obvious that mixtures 
containing lower levels of XG (35% and 50% LCS) showed a minor weight gain followed by 
a marked weight loss, as a result of the disintegration of LCS. On the other hand, mixtures 
containing 15-25% LCS showed high swelling capacity but to a lower extent than XG. This 
can be explained by the distribution of LCS molecules between XG chains, as illustrated in 
Figure 3, which lowers the contact between water molecules and XG; hence, swelling was 
reduced.  
Based on the results obtained from MDs, RSM, swelling and in-vitro release studies, the 
optimum release of MS, which complies with the USP specifications, was attained using a 
formulation containing 15% LCS (w/w). Thus, it was compared to the reference preparation 
(Betaloc® ZOK). Similarity factor, ƒ2, was calculated for the comparison using equation 6. 
Equation 6. 
𝑓2 = 50log {[1 +  (
1
𝑛






 × 100} 
where n is the number of time intervals, t is time, Rt and Tt are the accumulative percentages of 
drug release at time t for reference and test formulations, respectively. According to the 
guidelines, f2 values greater than 50 indicates a similar release profile between the two studied 
formulations,61 the f2 value for the 15% LCS formulation was 68 indicating a high similarity in 
the release of MS from the formulation with the reference product.  
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Tablet preparations containing 15% of LCS were used for further evaluation and investigation 
of swelling and drug release characteristics. Dissolution data obtained for MS were fitted to 
different release models in order to evaluate the kinetics of drug release from the matrix.62,63 
The in-vitro release mechanism of MS from the 15% LCS formulation (Table 4) showed a 
good fit to zero-order, first-order and Higuchi models (R2 > 0.95). This indicates the complexity 
of the prepared delivery system where different mechanisms are involved in MS release from 
the LCS/XG matrix.  
Table 4 In-vitro release parameters for MS from 15 % (w/w) LCS matrix tablets. 
Formulation 
Correlation coefficient (R2) Release 
exponent (n) Zero-order First-order Higuchi Koresmeyer-Peppas 
15% LCS 0.952 0.989 0.966 0.992 0.63 
 
In general, the mechanism of drug release from hydrophilic matrices is governed by: (i) wetting 
of the surface of the tablet, (ii) penetration of the media into the tablet, (iii) hydrogel formation 
(swelling), (iv) drug diffusion through the formed hydrogel, and (v) polymer relaxation and/or 
erosion.58,64 Considering the hydrophilic nature of LCS and XG in addition to the formation of 
an insoluble hydrogel layer (PEC) on the surface of their corresponding tablets, release is 
proposed to be governed by the swelling of the matrix to form the PEC layer and the diffusion 
of the drug through the insoluble layer formed. The Koresmeyer-Peppas exponent (0.63) for 
the 15% LCS preparation supports the hypothesis that the release of MS occurs via non-Fickian 
diffusion, which suggests that the diffusion of water molecules into the matrix together with 
polymer relaxation due to swelling are the factors that control the rate of MS release from the 
matrix.  
The data in Figure 8, shows that the radius of the tablets started to increase from the beginning 
of the dissolution process reaching the maximum radius after 12 h. This implies that the 
diffusion of water molecules plays an important role in drug release in the first 12 h of the 
dissolution process. After 12 h, the tablet was full hydrated and polymer relaxation reached a 
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maximum. Importantly, at the start of tablet dissolution and prior to complete film formation 
(0-2 h), around 12% of the tablet was eroded (6%/h), whereas during the stage of diffusion and 
polymer relaxation (2-12 h), a significant decrease in the rate of matrix erosion was noticed 
(0.7%/h) and only ~7% of the matrix was eroded. This indicates that the formation of PECs 
between XG and LCS prevents further polymer erosion and minimize its effect on drug release 
from the tablet.65 In the later stages of dissolution, the rate of polymer erosion was slightly 
increased (~1.8%/h) and the remaining mass of tablets at the end of the dissolution process was 
~ 65%.   
 
Figure 8 Remaining mass (red) and radial swelling (blue) % increase of the 15% LCS tablets during 
dissolution in phosphate buffer. Values represent mean ± SD (n=6). 
To test the suggested MS release mechanisms and assess the significance of diffusion and 
polymer relaxation processes on the release, the Peppas-Sahlin equation (Equation 7) was used. 
Equation 7.  
𝑄 = 𝑘1𝑡
𝑚 +  𝑘2𝑡
2𝑚  
where Q is the rate of drug release. The first term on the right-hand side of the equation 
represent the Fickian diffusion contribution, while the second term represents the polymer 
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relaxation contribution; k1 and k2 are the diffusion and relaxation rate constants, respectively 
and m is a constant that is related to the CR system. Results are presented in Table 5. Since k2 
> k1, it can be concluded that polymer relaxation (swelling) mechanism is the predominant 
mechanism for the drug release from the 15% LCS formulation. This is in agreement with the 
work of Gohel et al. who found that the release of MS from tablets containing XG, as the sole 
drug release controlling agent, is governed by XG relaxation.56 On the other hand, when non-
ionic natural polymers were used to sustain the release of MS (guar gum and badam gum), drug 
diffusion was the dominant factor in the control of the rate of release of MS from the tablets.59,66   
Table 5 Pappas-Sahlin release parameters for MS from 15 % (w/w) LCS matrix tablets. 
Formulation  k1 k2 m R2  
LCS 15% -22.88 34.45 0.23 0.9975 
 
Evaluation of drug distribution during dissolution using Raman mapping 
Imaging and mapping of APIs using vibrational spectroscopy methods have gained wide 
interest in the field of pharmaceutical formulation and process analytical technology. 
Vibrational spectroscopic techniques, infra-red and Raman spectroscopy, allow the continuous 
monitoring of APIs during processing which helps to evaluate the effect of formulation 
variables on the final product performance.67,68 Recently, vibrational spectroscopy techniques 
have been employed in tablet dissolution studies in order to obtain a better understanding of 
the process of drug release from pharmaceutical formulations and to monitor drug distribution 
within it.69,70 Since the Raman intensity of water is very weak compared to IR,71 Raman 
spectroscopy was chosen to monitor MS distribution between the dry core region and the 
hydrated gel layer during the time of swelling/dissolution. Raman spectra of pure MS, LCS 
and XG were obtained to determine the characteristic Raman shifts to be used during mapping 
to distinguish MS from the polymeric mixture (Figure 9). The model drug, MS, showed several 
characteristic vibrational bands in which it can be distinguished from the polymeric mixture. 
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The most intense vibrational bands appeared at 818, 964 and 1209 cm-1. Therefore, Raman 
mapping was performed in the region between 700 and 1400 cm-1. 
 
Figure 9 Raman spectra of MS, LCS and XG powders using a 785 nm laser.  
Figure 10 shows the morphological changes in the course of dissolution time on the surface of 
LCS-XG tablets and the drug distribution between the core and the gel layer during tablet 
dissolution. The highest concentration of the drug within the mapped area is presented in red 
whereas the lowest is represented in blue. It can be noticed that MS was more localized in the 
dry core for the first 4 h of the dissolution. A very small fraction of the drug migrated from the 
dry core to the gel layer at 1 h. Since the tablets were formulated from a physical mixture of 
the polymers where the drug is uniformly dispersed within the matrix, the fraction of the drug 
in the gel layer could be the fraction that was already available in the outer part of the tablet 
when the polymers started to absorb water from the dissolution media. A higher fraction of the 
drug moves from the core to the hydrogel layer with time reaching an almost equal distribution 


























































hydrated, and it was difficult to distinguish the core from the hydrated layer. After 12 h, tablets 
were fully swollen and hydrated with no different regions. Thus, Raman mapping was carried 
out for 12 h.  
Snapshots from the video images of the top surface of the tablets were recorded during 
dissolution to monitor PEC formation between XG and LCS. It can be noticed that after 1 h of 
dissolution a film started to form on the top surface of the tablets. The formation of the film 
was complete after 2 h and its integrity was maintained at 4 h. Film formation on the surface 
of tablets is verified by data in the literature.64 It was found that tablets comprising CS and 
anionic polymers such as XG, sodium alginate and carrageenan can form films on tablet 
surfaces during dissolution. Phaechamud and Ritthidej reported the formation of a porous film 
on the surface of tablets comprising CS-XG. They noted that the film was denser after 4 h of 
dissolution and suggested that it plays a role in drug diffusion and release into the media.72 
Shao et al., found a profound reduction in swelling and erosion ratios of XG-CS tablets 
following the complete formation of PEC on the surface.73 Li et al confirmed the previous 
finding when studying the swelling and release behaviour of CS-sodium alginate tablets.62 It 
can be noticed from swelling data using 15% LCS (Figure 7b) that a large amount of water was 
absorbed by the matrix after 1 h dissolution, resulting in a tablet weight increase of > 200 %. 
However, and following the complete formation of the film on the surface of the tablet, the 
weight-gain of the swollen tablets levelled off between 2-6 h where the percentage weight gain 
increased only from ~260 – 420 %, indicating a swelling rate of ~ 40%/h compared to 200%/h 
for the first hour. A sharp increase in weight gain to around 600% occurred after 8 h (100%/h). 
From the video images obtained in Figure 10, it can be noted that the developed film started 
losing its integrity at 8 h and adopted a porous structure rather than the firm and continuous 
one which occurred between 2-4 h. At 12 h, the film became more porous resulting in full 




Figure 10 Images on the left side are snapshots obtained from the top surface of the swollen tablets 
during dissolution (magnification x10). Raman maps, in the mid and right side, show MS distribution 
between the dry core and the hydrated gel layers of XG-15% LCS tablets as a function of dissolution 
time. The area mapped was 720×720 µm2 using an x10 objective. 
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Effect of the pH and ionic strength (µ) of the dissolution media on the release of MS from 
LCS-XG tablets 
Since electrostatic forces are the dominant factor that governs the interaction between LCS and 
XG, ionization of each polymer will have an influence on PEC formation; as was established 
in previous work.50 Therefore, the formulation containing 15% LCS was evaluated at different 
pH and µ values and then compared to a formulation comprising XG as the sole polymer to 
assess the effect of adding LCS to the preparation in terms of drug release and matrix swelling.  
Release of MS from XG based tablets was markedly higher at pH 1.2 than pH 6.8 (Figure 11a, 
b). This can be explained by the protonation of the free carboxylic groups present in the 
structure of XG at pH values lower than its pKa (3.1).74 According to the Henderson-
Hasselbalch equation, the concentration of protonated carboxyl groups (-COOH) is ~79 times 
the unprotonated (-COO-) value at pH 1.2 (Table 7). As a result, the repulsive forces between 
-COO- is decreased and XG maintains its ordered helical conformation. Consequently, the drug 
retardation ability of XG is decreased due to the reduction in water uptake capability. In 
contrast, the negative charge density of XG is enhanced in acetate and phosphate buffers at pH 
4.5 and 6.8, respectively, allowing XG to adopt a disordered coiled conformation. For the 15% 
LCS preparation, LCS on the tablet surface is fully protonated at pH 1.2, while XG is unionized. 
Therefore, no electrostatic interactions occurred between LCS and XG and higher drug release 
rate was noticed. When the pH is increased to 4.5 and 6.8, both XG and LCS become almost 
fully ionized. Electrostatic attractive forces between the oppositely charged groups of XG and 
LCS lead to the detected close contact between the two polymers during MD simulations, and 
the observed low RMSD fluctuation (Figure 2a). As a result, an insoluble PEC is formed on 
the surface of the tablet. The foregoing assertion is supported by the high positive ∆Gsolv values 
(>190 kcal/mol) displayed by the LCS-XG complexes. This indicates unfavourable interactions 
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of the complexes with aqueous media. In other words, an insoluble and highly stable complex 
is formed between LCS and XG. 
Table 6 Values for the [unprotonated]/[protonated] ratio of LCS and XG in the dissolution media used. 
Material pH 1.2 pH 4.5 pH 6.8 
XG 1/79 25/1 5000/1 
LCS 0/1 1/63 2/1 
 
The impact of ionic strength of the dissolution media on the swelling behaviour of the two 
compacts is presented in the data in Figure 11e and f. The high sensitivity of XG to salt 
concentration in the dissolution medium is clear. A significant decrease in weight gain, around 
two thirds, was found when the µ value increased from 0 to 0.4 M. Counter-ions cause a 
reduction in repulsion forces between XG chains. Hence, a rigid helical confirmation stabilized 
by hydrogen bonds is formed. As a result, a higher fraction of drug is released from the tablets 
(Figure 11c). MS was fully released after 12 h when the µ = 0.4 M. Calculated ƒ2 values of 
new release profiles compared to the original dissolution profile were 55.4, 45.6, and 35.0 when 
µ = 0.1 M, 0.2 M and 0.4 M, respectively. 
Interestingly, incorporating LCS seems to decrease XG sensitivity to minor changes in ionic 
strength. Tablets comprising 15% LCS displayed an insignificant increase in drug release with 
elevated µ values of the dissolution media (Figure 11d). A change of no more than 10% in MS 
release at each time interval was detected. Calculated ƒ2 values for the dissolution profiles at µ 
= 0.1, 0.2 and 0.4 M were 68.5, 60.1 and 54.5, respectively, when compared to the dissolution 
profile of MS from 15% LCS at 0 M. From the average structures of the LCS-XG complexes 
determined by MDs, it can be noticed that LCS molecules were embedded between the XG 
chains. Hence, the incorporated LCS molecules shield XG, minimize the interaction of COO- 
groups with counter-ions present in the dissolution media, and decrease the susceptibility of 




Figure 11 (a-d) The influence of dissolution media pH (at pH 1.2, 4.5 and 6.8) and ionic strength (at µ 
= 0, 0.1, 0.2 and 0.4 M) on the in-vitro release of MS from XG and 15% LCS tablets. Values represent 
mean ± SD (n=6). (e and f) Degree of swelling of XG and 15% LCS formulations from phosphate 
buffer pH 6.8 at different µ. Values represent mean ± SD (n=6). (*) denotes insignificant difference in 
the mean % swelling when µ= 0.1, 0.2 or 0.4 M from the mean % swelling of tablets in 0M dissolution 
media (p>0.05), whereas (**) denotes a significant difference in the mean (p<0.05)  








A drug release study from tablets comprising XG and 15% HCS was carried out as a 
comparison with the results obtained from LCS formulation and to assess the performance of 
the XG-HCS based matrix in controlling the release of MS at different pH and µ values of the 
dissolution media. Data presented in Figure 12 demonstrates the capability of the matrix to 
sustain the release of MS. It is obvious that the extent and rate of drug release is highly 
dependent on the pH and µ of the dissolution media where the drug was fully released after ~ 
12 h at low pH (1.2) and high µ (0.2 and 0.4 M) dissolution media. At pH 4.5 and 6.8, the full 
release of the drug was obtained after 16-20 h. In addition, and when compared to the LCS 
formulation, a burst release of MS from the formulation can be noticed where around 30% of 
MS was released in the first two hours (pH 6.8) whereas LCS 15% formulation released < 20% 
of MS after 2 h of dissolution. These results confirm the finding of MDs which showed that 
the interaction is more favourable between LCS-XG complexes than HCS-XG. Therefore, 
more time is needed for HCS to form PEC films on the surface of the tablets; thus, a higher 
fraction of the drug is dissolved at the beginning of dissolution. Almost similar release profiles 
of MS were obtained when lowering the pH of the dissolution medium to 4.5. In HCl (pH 1.2), 
40% of the incorporated dose was released after 2 h and the drug was fully released (> 85%) 
after 8 h. Likewise, HCS was not able to overcome the dependency of drug release rate from 
XG matrixes on the ionic strength of the dissolution media where the fraction of MS released 
in phosphate buffer solution with added 0.1 M NaCl was 5-10% higher than phosphate buffer 
alone. A remarkable increase in the cumulative MS released from the XG-HCS matrix was 
noticed when adding 0.4 M NaCl to the buffer where a 15-25% difference was noticed at each 
time point when compared to the phosphate buffer. The results obtained are in good agreement 
with the studies reported in the literature where LCS showed better CR than HCS when 
combined with XG.30,39 However, the behaviour and the CR efficiency of the matrices at 




Figure 12 MS release profiles from XG-15% HCS tablets using dissolution media of different pH (1.2, 
4.5 and 6.8) and different µ values (0, 0.1, 0.2 and 0.4 M). Values represent mean ± SD (n=6). 
 
Dose dumping evaluation 
Dose dumping is one of the main drawbacks encountered when using controlled release drug 
delivery.75 The solubility of some polymers and other incorporated inactive ingredients might 
be enhanced in the presence of alcohol. Thus, rapid drug release occurs in the first 1-2 hours 
which is referred to as (dose dumping).76 To test the robustness of the prepared formulation, 
in-vitro release studies for LCS (15%) in an acidic medium (HCl, pH 1.2) were carried out in 
the presence of ethanol. In the test preparation (LCS 15%), MS showed similar release profiles 
regardless of ethanol concentration within the dissolution media (Figure 13). On the other hand, 
dose dumping of MS occurred from the reference formulation (Betaloc ZOK®) when ethanol 
was introduced to the dissolution medium at concentrations ≥ 20 % (v/v). This can be explained 
by the hydrophilicity of XG and LCS together with their low solubility in ethanol which 
resulted in the observed, unaffected drug release. Whereas, the reference formulation contains 
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a wide range of hydrophobic polymers and inactive ingredients that are highly soluble in 
ethanol such as, silicon dioxide, ethylcellulose, titanium dioxide, and paraffin. Thus, release of 
MS from Betaloc ZOK® was enhanced. 
 
Figure 13 The influence of the presence of ethanol on the in-vitro release profile of MS from: 
(a) 15% LCS tablets and (b) the reference product at 0, 5, 20 and 40% (v/v) ethanol. Values represent 







Computational and drug release studies have demonstrated the superiority of LCS compared 
to HCS in controlling the release of the entrapped drug when being directly compressed with 
XG. MDs results suggested that XG forms more stable complexes with LCS compared to HCS. 
Furthermore, the conformational flexibility of XG chains has been shown to be higher and the 
time required for LCS-XG complexes to reach equilibrium shorter when LCS was incorporated 
at low fractions (i.e. 15%). RSM outputs revealed that the major factors determining the rate 
of MS release from XG-LCS based solid matrices are the P:D ratio and the weight percentage 
of LCS and that the optimum CR formulation can be obtained by using LCS ≤20%. The 
developed LCS-XG based tablets showed pH-insensitive CR characteristics when LCS was 
incorporated at 15% (w/w) using a P:D ratio of 4:1. Moreover, drug release results revealed 
that the ionic strength of the dissolution media (phosphate buffer) has no impact on tablet 
swelling and MS release from the 15% LCS matrix system. On the contrary, release profiles of 
MS from HCS-XG compacts showed high dependency on pH and ionic strength of the 
dissolution media. Results obtained from Raman mapping and swelling studies for the 15% 
LCS formulation showed that a self-assembled film was formed on the surface of the tablets 
due to polyelectrolyte complexation between the two polymers. Upon film formation, a 
reduction in tablet swelling and drug release was noticed; MS was shown to be more localized 
in the dry core of the tablets. At this stage, the rate of water penetration into the matrix and 
polymer relaxation are the main contributors to drug release from the matrix. Thereafter, the 
formed film started to break down causing the tablets to become fully hydrated and a reduction 
in the radial swelling of the gel layer occurs resulting in a uniform distribution of the drug 
within the matrix. The rate of drug diffusion through the hydrated tablet together with the rate 
of matrix erosion are suggested to govern the rate of drug release at this stage of dissolution. 
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The study reported herein addresses the utility of computational tools in predicting and 
minimizing the experimental work required to design and optimize drug delivery systems. In 
addition, it establishes the strong possibility of using a CR dosage form based on two 
biopolymers that is ready for large scale production using an accessible, cost-effective, and 
“simple” methodology. Further investigations toward the applicability of this system to a wide 
range of APIs, and on its capability to be used as a universal CR system are currently under 
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